Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 June 2017Website:
http://www.avenuetx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:48:20 GMTDividend
Analysts recommendations
Institutional Ownership
ATXI Latest News
Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC), Davidow now holds a 14.5% stake in the specialty pharmaceutical company.
What type of business is Avenue Therapeutics?
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
What sector is Avenue Therapeutics in?
Avenue Therapeutics is in the Healthcare sector
What industry is Avenue Therapeutics in?
Avenue Therapeutics is in the Biotechnology industry
What country is Avenue Therapeutics from?
Avenue Therapeutics is headquartered in United States
When did Avenue Therapeutics go public?
Avenue Therapeutics initial public offering (IPO) was on 27 June 2017
What is Avenue Therapeutics website?
https://www.avenuetx.com
Is Avenue Therapeutics in the S&P 500?
No, Avenue Therapeutics is not included in the S&P 500 index
Is Avenue Therapeutics in the NASDAQ 100?
No, Avenue Therapeutics is not included in the NASDAQ 100 index
Is Avenue Therapeutics in the Dow Jones?
No, Avenue Therapeutics is not included in the Dow Jones index
When does Avenue Therapeutics report earnings?
The next expected earnings date for Avenue Therapeutics is 09 August 2024